Brokerages forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce earnings per share (EPS) of ($0.97) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.10) and the highest estimate coming in at ($0.82). Adamas Pharmaceuticals posted earnings of ($1.26) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 23%. The business is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($3.77) per share for the current year, with EPS estimates ranging from ($4.29) to ($3.46). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.42) per share, with EPS estimates ranging from ($2.80) to ($2.12). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.13) by $0.05. The business had revenue of $11.67 million for the quarter, compared to analysts’ expectations of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%.
A number of equities analysts recently issued reports on the company. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 28th. Finally, Mizuho restated a “buy” rating and issued a $37.00 target price on shares of Revance Therapeutics in a report on Wednesday, April 24th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.91.
Large investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in Adamas Pharmaceuticals by 46.9% during the fourth quarter. Rhumbline Advisers now owns 29,781 shares of the specialty pharmaceutical company’s stock valued at $254,000 after acquiring an additional 9,514 shares during the period. BlackRock Inc. increased its stake in Adamas Pharmaceuticals by 9.3% during the fourth quarter. BlackRock Inc. now owns 2,064,758 shares of the specialty pharmaceutical company’s stock valued at $17,633,000 after acquiring an additional 174,844 shares during the period. Advisor Group Inc. increased its stake in Adamas Pharmaceuticals by 252.0% during the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 4,510 shares during the period. Citigroup Inc. increased its stake in Adamas Pharmaceuticals by 72.4% during the fourth quarter. Citigroup Inc. now owns 173,179 shares of the specialty pharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 72,701 shares during the period. Finally, Geode Capital Management LLC increased its stake in Adamas Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 232,900 shares of the specialty pharmaceutical company’s stock valued at $1,988,000 after acquiring an additional 14,902 shares during the period. 76.68% of the stock is owned by institutional investors.
Shares of NASDAQ ADMS traded down $0.06 during mid-day trading on Wednesday, reaching $5.94. The company had a trading volume of 2,110 shares, compared to its average volume of 314,785. The company has a debt-to-equity ratio of 2.00, a quick ratio of 6.86 and a current ratio of 7.03. The stock has a market capitalization of $162.72 million, a PE ratio of -1.22 and a beta of 1.72. The business has a 50-day moving average price of $5.27. Adamas Pharmaceuticals has a 1-year low of $4.20 and a 1-year high of $29.49.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Read More: What is a Roth IRA?
Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.